THE TREATMENT OF DISSEMINATED PROSTATE-CANCER WITH ESTRAMUSTINE

被引：1
|
作者：
ROSENTHAL, MA [1 ]
RAGHAVAN, D [1 ]
STUARTHARRIS, R [1 ]
ACKLAND, S [1 ]
GRYGIEL, J [1 ]
机构：
[1] ROYAL PRINCE ALFRED HOSP,UROL CANC RES UNIT,LEVEL E9,CAMPERDOWN,NSW 2050,AUSTRALIA
来源：
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY | 1992年 / 62卷 / 11期
关键词：
ESTRAMUSTINE; PROSTATE CANCER;
D O I：
10.1111/j.1445-2197.1992.tb06942.x
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Forty-three patients with disseminated prostate cancer, resistant to orchidectomy or hormone therapy with estramustine were treated. Of the 33 evaluable patients, three patients had stable disease and two had a partial tumour response according to National Prostatic Cancer Project criteria. Twenty-five patients (58%) showed improvement in pain and urinary symptoms. Ten patients (23%) had side effects requiring cessation of therapy. These results show that estramustine has a limited role in the treatment of advanced prostate cancer and that therapy is frequently associated with intolerable side effects.
引用
收藏
页码：871 / 873
页数：3
相关论文
共 50 条
  • [31] Potentiation of focal ultrasound treatment of prostate cancer by concomitant chemotherapy with estramustine phosphate and paclitaxel
    Paparel, P
    Chapelon, JY
    Curiel, L
    Rabilloud, M
    Chesnais, S
    Gelet, A
    PROGRES EN UROLOGIE, 2004, 14 (01): : 40 - 46
  • [32] Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer
    Attivissimo, LA
    Fetten, JV
    Kreis, W
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (06): : 581 - 583
  • [33] IN-VITRO PROPAGATED DENDRITIC CELLS FROM PROSTATE-CANCER PATIENTS AS A COMPONENT OF PROSTATE-CANCER IMMUNOTHERAPY
    TJOA, B
    ERICKSON, S
    BARREN, R
    RAGDE, H
    KENNY, G
    BOYNTON, A
    MURPHY, G
    PROSTATE, 1995, 27 (02) : 63 - 69
  • [34] A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer
    Dahmani, Ahmed
    de Plater, Ludmilla
    Guyader, Charlotte
    Fontaine, Jean-Jacques
    Berniard, Aurelie
    Assayag, Franck
    Beuzeboc, Philippe
    Marangoni, Elisabetta
    Nemati, Fariba
    Poupon, Marie-France
    Pasik, Christophe
    Oudard, Stephane
    Decaudin, Didier
    ANTI-CANCER DRUGS, 2010, 21 (10) : 927 - 931
  • [35] TUMOR-MARKERS IN PROSTATE-CANCER
    COOPER, EH
    ROBINSON, MRG
    WHELAN, P
    FERRO, MA
    CANCER, 1992, 70 (01) : 225 - 229
  • [36] Molecular biology of prostate-cancer pathogenesis
    Shand, Randi L.
    Gelmann, Edward R.
    CURRENT OPINION IN UROLOGY, 2006, 16 (03) : 123 - 131
  • [37] BIOMARKERS ASSOCIATED WITH PROSTATE-CANCER PROGRESSION
    ZHAU, HE
    PISTERS, LL
    HALL, MC
    ZHAO, LS
    TRONCOSO, P
    POLLACK, A
    CHUNG, LWK
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 208 - 216
  • [38] SEXUAL REHABILITATION OF THE PROSTATE-CANCER PATIENT
    SPROUSE, DO
    CANCER, 1995, 75 (07) : 1954 - 1956
  • [39] PROSTATE-CANCER SCREENING - APPROPRIATE CHOICES
    LITTRUP, PJ
    CANCER, 1994, 74 (07) : 2016 - 2022
  • [40] PROGNOSTIC FACTORS IN METASTATIC PROSTATE-CANCER
    MATZKIN, H
    PERITO, PE
    SOLOWAY, MS
    CANCER, 1993, 72 (12) : 3788 - 3792
12345